Adoptive cellular immunotherapy using virus-specific CTL lines engineered with glucocorticoid receptor (GR/NR3C1) knockout to resist steroid-mediated suppression/apoptosis; HLA-restricted recognition of adenovirus, BK virus, CMV, JC virus, or SARS-CoV-2 antigens on infected cells, leading to perforin/granzyme-mediated killing and antiviral cytokine release; administered intravenously with possible repeat dosing.
Adoptively transferred, virus-specific CTLs recognize viral peptides presented on HLA molecules via their native TCRs and eliminate infected cells through perforin/granzyme-mediated cytolysis and antiviral cytokine secretion. The cells are engineered with glucocorticoid receptor (NR3C1) knockout to resist steroid-induced suppression and apoptosis, improving persistence and antiviral activity in immunosuppressed patients.
YES
DIRECT
Virus-specific CTLs recognize adenoviral peptide–HLA complexes via the TCR and kill infected cells by perforin/granzyme-mediated apoptosis (and potentially Fas–FasL signaling).
Adoptive cellular immunotherapy using virus-specific CTL lines engineered with glucocorticoid receptor (GR/NR3C1) knockout to resist steroid-mediated suppression/apoptosis; HLA-restricted recognition of adenovirus, BK virus, CMV, JC virus, or SARS-CoV-2 antigens on infected cells, leading to perforin/granzyme-mediated killing and antiviral cytokine release; administered intravenously with possible repeat dosing.
Adoptively transferred, virus-specific CTLs recognize viral peptides presented on HLA molecules via their native TCRs and eliminate infected cells through perforin/granzyme-mediated cytolysis and antiviral cytokine secretion. The cells are engineered with glucocorticoid receptor (NR3C1) knockout to resist steroid-induced suppression and apoptosis, improving persistence and antiviral activity in immunosuppressed patients.
YES
DIRECT
Virus-specific CTLs recognize BK polyomavirus peptides presented on HLA via their TCR and directly kill infected cells through perforin/granzyme-mediated apoptosis (and Fas/FasL pathways).
Adoptive cellular immunotherapy using virus-specific CTL lines engineered with glucocorticoid receptor (GR/NR3C1) knockout to resist steroid-mediated suppression/apoptosis; HLA-restricted recognition of adenovirus, BK virus, CMV, JC virus, or SARS-CoV-2 antigens on infected cells, leading to perforin/granzyme-mediated killing and antiviral cytokine release; administered intravenously with possible repeat dosing.
Adoptively transferred, virus-specific CTLs recognize viral peptides presented on HLA molecules via their native TCRs and eliminate infected cells through perforin/granzyme-mediated cytolysis and antiviral cytokine secretion. The cells are engineered with glucocorticoid receptor (NR3C1) knockout to resist steroid-induced suppression and apoptosis, improving persistence and antiviral activity in immunosuppressed patients.
YES
DIRECT
Virus-specific CTLs recognize CMV peptide–HLA complexes via their TCR and directly lyse infected cells through perforin/granzyme-mediated cytotoxicity.
Adoptive cellular immunotherapy using virus-specific CTL lines engineered with glucocorticoid receptor (GR/NR3C1) knockout to resist steroid-mediated suppression/apoptosis; HLA-restricted recognition of adenovirus, BK virus, CMV, JC virus, or SARS-CoV-2 antigens on infected cells, leading to perforin/granzyme-mediated killing and antiviral cytokine release; administered intravenously with possible repeat dosing.
Adoptively transferred, virus-specific CTLs recognize viral peptides presented on HLA molecules via their native TCRs and eliminate infected cells through perforin/granzyme-mediated cytolysis and antiviral cytokine secretion. The cells are engineered with glucocorticoid receptor (NR3C1) knockout to resist steroid-induced suppression and apoptosis, improving persistence and antiviral activity in immunosuppressed patients.
YES
DIRECT
Virus-specific CTLs recognize JC polyomavirus peptide–HLA complexes via their TCR and kill infected cells by perforin/granzyme-mediated cytolysis (and Fas–FasL apoptosis).
Adoptive cellular immunotherapy using virus-specific CTL lines engineered with glucocorticoid receptor (GR/NR3C1) knockout to resist steroid-mediated suppression/apoptosis; HLA-restricted recognition of adenovirus, BK virus, CMV, JC virus, or SARS-CoV-2 antigens on infected cells, leading to perforin/granzyme-mediated killing and antiviral cytokine release; administered intravenously with possible repeat dosing.
Adoptively transferred, virus-specific CTLs recognize viral peptides presented on HLA molecules via their native TCRs and eliminate infected cells through perforin/granzyme-mediated cytolysis and antiviral cytokine secretion. The cells are engineered with glucocorticoid receptor (NR3C1) knockout to resist steroid-induced suppression and apoptosis, improving persistence and antiviral activity in immunosuppressed patients.
YES
DIRECT
Virus-specific CTLs recognize SARS‑CoV‑2 peptide–HLA complexes via their TCR and kill infected cells through perforin/granzyme-mediated cytolysis (with possible Fas/FasL contribution).